Overexpression of plasma apolipoprotein CIII (apo CIII) causes hypertriglyceridemia in transgenic mice. A genetically variant form of the human apo CIII promoter, containing five single base pair changes, has been shown to be associated with severe hypertriglyceridemia in a patient population. In animals and in cultured cells the apo CIII gene is transcriptionally downregulated by insulin. In this study we demonstrate that, unlike the wild-type promoter, the variant promoter was defective in its response to insulin treatment, remaining constitutively active at all concentrations of insulin. The loss of insulin regulation was mapped to polymorphic sites at -482 and -455, which fall within a previously identified insulin response element. Loss of insulin regulation could result in overexpression of the apo CIII gene and contribute to the development of hypertriglyceridemia. The variant apo Cm promoter is common in the human population and may represent a major contributing factor to the development of hypertriglyceridemia. (J. Clin. Invest. 1995. 96:2601-2605
Introduction
apo CIII is a constituent of triglyceride (TG)' rich lipoproteins and is an important regulator of plasma TG concentrations (1, 2) . Studies in transgenic mice have demonstrated that the level of apo CIII has a direct and dramatic influence on plasma TG levels (3, 4) . As little as 40% additional apo CIII results in more than a doubling of plasma TGs. Related findings have been reported in clinical studies in which apo CIII levels have been observed to be correlated with elevated plasma TG levels and delayed clearance of TG-rich lipoproteins (5) (6) (7) . Finally, genetic studies have demonstrated a strong association of a polymorphism in the 3' UTR of the human apo CIII gene with hypertriglyceridemia in several distinct populations (8) (9) (10) (11) (12) . Taken together, these studies strongly suggest that expression of the apo CIII gene is an important determinant of plasma TG levels in the human population.
The regulation of apo CIII gene expression appears to occur primarily at the level of transcription. In liver cells, the transcriptional activity of the gene is regulated by a variety of agents, including inflammatory cytokines like IL-1 (13) and hypolipidemic agents such as fibric acids (14) . In addition, we have demonstrated recently that the apo CHI gene is regulated by insulin in animals and in cultured hepatocytes ( 15 ) . In these studies, treatment of insulin-deficient diabetic mice with insulin resulted in a 2.5-fold decrease in hepatic apo CIII mRNA levels and a corresponding decrease in apo CIII gene transcriptional activity. In addition, it was shown that insulin treatment of HepG2 cells transfected with an apo CIII luciferase reporter construction caused a dose-dependent twofold reduction in apo CIII transcriptional activity.
Recently, the promoter of the human apo CIII gene was found to be genetically polymorphic, containing five sites of single base pair sequence variation between -641 and -455 ( Fig. 1) . In an association study, a haplotype of the CIII gene containing all five sequence changes was found to be associated with an increased risk of hypertriglyceridemia ( 16) . One possible explanation for the association of the variant promoter with elevated triglycerides is that one or more of these changes increases the transcriptional activity of the apo CIII gene, thereby causing an increase in apo CIII levels and inducing the development of hypertriglyceridemia. The goal of the current study is to determine if the DNA sequence changes that occur in the variant promoter cause a change in the transcriptional activity of the apo CIII gene.
Methods
Plasmids. CAT transfected for 4 h and allowed to recover in MEM plus 10% fetal bovine serum for 48 h, followed by insulin treatment for 6 h in serumfree media. Cells were harvested and luciferase activity was measured and normalized to total protein as described (15) . Experiments with insulin treatment were carried out in the absence of a f-gal internal reference plasmid. Statistical significance was calculated using the Student's two-tailed t test.
Gel shifts. Nuclear extracts were prepared from liver isolated from hyperglycemic female Sprague-Dawley rats. Hyperglycemia was induced by a 65 mg/kg intravenous injection of streptozotocin 12 d before time of killing. Liver tissue was disrupted in a Teflon glass homogenizer, and the cells were lysed in hypotonic buffer. Nuclei were extracted essentially as described (19) . Gel mobility shift assay was performed as described (17) , in the presence of 0.5 mM MgCl2, 0.25 ng labeled probe (50,000 cpm), and 9 Msg of nuclear extract. Gels were analyzed on a Molecular Dynamics Phosphorlmager (Sunnyvale, CA).
Results and Discussion
The DNA sequences of the wild-type and variant versions of the apo CIII promoter are shown in Fig. 1 Although basal activity was not strongly affected, it remained a possibility that one or more of these changes affected the ability of the promoter to respond to cellular signals that modulate apo CIII transcription. Two of the five sites of sequence variation (at positions -482 and -455) fall within a region that has been characterized recently by mutational analysis as a functional insulin response element (Li, W. W., and T. Leff, manuscript in preparation). In addition, the -455 site is within a sequence that is similar to an insulin response element found in the rat PEPCK gene promoter (Fig. 1 B) . These observations suggested that the variant promoter might be defective in its ability to be downregulated by insulin. To (Fig. 2) . The degree of downregulation was consistent with that observed in animal studies (15) . In contrast, both the variant (22222) promoter and the recombinant promoter containing the variant sequence at the two downstream sites (11122) were defective in their response to insulin treatment, remaining at elevated levels at all doses of insulin (Fig. 2) , indicating that the defective insulin response is due to changes at the two downstream sites. To determine if variation at one or both of these sites is responsible for the loss of insulin regulation, each was individually reconstructed into the wild-type promoter background and transfected into HepG2 cells. Neither the 11121 nor the 11112 construction was responsive to insulin treatment (Fig. 2) , demonstrating that a single base pair change at either the -482 site or the -455 site is sufficient to abolish the insulin responsiveness of the apo CIII promoter. These findings suggest that a subject with a variant promoter would have an apo CIII gene that was not properly downregulated by insulin. In an otherwise insulin-responsive subject, this would result in a relative overexpression of the apo CIII gene, leading to increased susceptibility to the development of hypertriglyceridemia. It may be significant that several of the variant constructions show a mild dose-dependent stimulation of transcription by insulin (22222, 11122, and 11 121, Fig. 2 A) and increased basal transcriptional activity ( 11122, Table I ). These changes could further increase apo CIII production in patients containing a variant allele. The possibility that the variant promoter configuration could lead to overexpression of the apo CIII gene and a tendency to develop hypertriglyceridemia is consistent with results from a previous genetic association study (16) . In this study apo CIII alleles consisting of the 22222 or 22212 promoter variants, and the less common (S2) allele of a polymorphic SstI site in the 3' UTR of the apo CIII gene, were associated with an increased risk of hypertriglyceridemia. These findings suggest that, in at least some genetic backgrounds, the interact with specific DNA binding proteins in rat liver nuclear extracts. As presented in Fig. 3 , two DNA binding activities interacted with an oligonucleotide probe representing the C3IRE. The binding of these two proteins could be completed by the wild-type oligonucleotide (self-competition), but not by the same amount of a variant oligonucleotide containing either a single base pair change at -455 or the double change (-455 and -482) (Fig. 3, lanes 3, 5, and 7) . In contrast, the C3IRE oligonucleotide containing the single base pair change at -482 was nearly as good a competitor as the wild-type oligonucleotide (Fig. 3, lanes 3 and 6) , indicating that the change at -482 did not affect the binding of these two proteins to the C3IRE. This was an unexpected result in light of the clear transcriptional effect of a sequence change at the -482 site (Fig. 2) . It is possible that the transcription factors interacting with sequences around the -482 site in vivo are not present in our nuclear extract preparations. It should be noted that, in the human population, the -482 sequence variant rarely appears without the -455 sequence variant ( 16) . For this reason the in vitro behavior of the isolated -482 mutation is of limited significance with regard to the role of the variant promoter in human physiology. Taken together, these results demonstrate that a single base pair change at the -455 site reduces the affinity of the C3IRE for specific DNA binding proteins, and provides a potential explanation for the inability of the variant apo CIII promoter allele to respond to insulin.
Several instances of inherited defects in transcriptional regulation have been described (for examples see references [20] [21] [22] [23] . The variation in the promoter of the apo CIII gene is, to our knowledge, the first example of a genetic polymorphism in an insulin response element. The defective apo CIII insulin response element can be considered an example of insulin resistance at the level of the gene. Although overexpression of human apo CIII does not cause diabetes in transgenic mice (24) , the paradigm of insulin resistance at the transcriptional level, as exemplified by apo CIII promoter, may prove applicable to other genes. Insulin-resistant transcriptional regulation of genes directly involved in glucose metabolism could potentially play a role in the development of general insulin resistance and noninsulin-dependent diabetes mellitus.
